Dyne Therapeutics
83 hedge funds and large institutions have $573M invested in Dyne Therapeutics in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 24 increasing their positions, 21 reducing their positions, and 9 closing their positions.
78% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 9
14% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 21
9% more funds holding
Funds holding: 76 → 83 (+7)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.15% less ownership
Funds ownership: 69.92% → 68.77% (-1.1%)
24% less capital invested
Capital invested by funds: $753M → $573M (-$180M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$27.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.59M |
| 3 |
Renaissance Technologies
New York
|
+$2.49M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$2.08M |
| 5 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$2.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$26.8M |
| 2 |
DM
Deerfield Management
New York
|
-$16.6M |
| 3 |
O
OrbiMed
New York
|
-$7.36M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$4.1M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.64M |
DYN Hedge Fund Activity: Q3 2021 in Review
83 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q3 2021, worth a combined $573M — down 24% from $753M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new DYN positions and 9 closed out — a net gain of 7 holders — while 24 added to existing stakes and 21 trimmed.
The largest buyer was Logos Global Management, adding an estimated $27.7M. The largest seller was Wellington Management Group, cutting an estimated $26.8M.
- 83 institutional investors held Dyne Therapeutics (DYN) as of Q3 2021, up from 76 in Q2 2021.
- Funds reported $573M of Dyne Therapeutics stock for Q3 2021, down 24% quarter-over-quarter.
- 16 funds opened new Dyne Therapeutics positions in Q3 2021 and 9 closed out, a net change of +7 holders.
- The largest Dyne Therapeutics buyer in Q3 2021 was Logos Global Management, an estimated $27.7M added.
- The largest Dyne Therapeutics seller in Q3 2021 was Wellington Management Group, an estimated $26.8M sold.
Based on aggregated 13F filings for Q3 2021.